250 related articles for article (PubMed ID: 25633079)
1. Novel molecular targets for urothelial carcinoma.
Faltas BM; Karir BS; Tagawa ST; Rosenberg JE
Expert Opin Ther Targets; 2015 Apr; 19(4):515-25. PubMed ID: 25633079
[TBL] [Abstract][Full Text] [Related]
2. Novel molecular targets for the therapy of urothelial carcinoma.
Jana BR; Galsky MD; Hahn NM; Milowsky MI; Sonpavde G
Expert Opin Ther Targets; 2012 May; 16(5):499-513. PubMed ID: 22510032
[TBL] [Abstract][Full Text] [Related]
3. Emerging drugs for urothelial (bladder) cancer.
Cumberbatch K; He T; Thorogood Z; Gartrell BA
Expert Opin Emerg Drugs; 2017 Jun; 22(2):149-164. PubMed ID: 28556678
[TBL] [Abstract][Full Text] [Related]
4. Novel Molecular Targets for the Therapy of Urothelial Cancer.
Jana BR; Zhou Y
Anticancer Res; 2015 Sep; 35(9):4557-67. PubMed ID: 26254343
[TBL] [Abstract][Full Text] [Related]
5. Spectrum of genomic alterations in FGFR3: current appraisal of the potential role of FGFR3 in advanced urothelial carcinoma.
Sethakorn N; O'Donnell PH
BJU Int; 2016 Nov; 118(5):681-691. PubMed ID: 27271022
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapy in advanced bladder cancer: what have we learned?
Jordan EJ; Iyer G
Urol Clin North Am; 2015 May; 42(2):253-62, ix. PubMed ID: 25882566
[TBL] [Abstract][Full Text] [Related]
7. Emerging first line treatment options for bladder cancer: a review of phase II and III therapies in the pipeline.
Jamy O; Sonpavde G
Expert Opin Emerg Drugs; 2017 Dec; 22(4):347-355. PubMed ID: 29226734
[TBL] [Abstract][Full Text] [Related]
8. Systemic treatments for metastatic urothelial carcinoma.
Lalani AA; Sonpavde GP
Expert Opin Pharmacother; 2019 Feb; 20(2):201-208. PubMed ID: 30412003
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel for the treatment of bladder cancer.
Albany C; Sonpavde G
Expert Opin Investig Drugs; 2015; 24(12):1657-64. PubMed ID: 26535615
[TBL] [Abstract][Full Text] [Related]
10. Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial Carcinoma.
Kurtoglu M; Davarpanah NN; Qin R; Powles T; Rosenberg JE; Apolo AB
Clin Genitourin Cancer; 2015 Oct; 13(5):410-20. PubMed ID: 25862322
[TBL] [Abstract][Full Text] [Related]
11. Molecular biology and targeted therapies for urothelial carcinoma.
Seront E; Machiels JP
Cancer Treat Rev; 2015 Apr; 41(4):341-53. PubMed ID: 25828962
[TBL] [Abstract][Full Text] [Related]
12. Targeted therapy in advanced urothelial carcinoma.
Verdoorn BP; Kessler ER; Flaig TW
Oncology (Williston Park); 2013 Mar; 27(3):219-26. PubMed ID: 23687793
[TBL] [Abstract][Full Text] [Related]
13. Targeted agents in second-line bladder cancer therapy.
Gerullis H; Otto T; Ecke TH
Anticancer Drugs; 2012 Nov; 23(10):1003-15. PubMed ID: 22914698
[TBL] [Abstract][Full Text] [Related]
14. Dovitinib: rationale, preclinical and early clinical data in urothelial carcinoma of the bladder.
Mazzola CR; Siddiqui KM; Billia M; Chin J
Expert Opin Investig Drugs; 2014 Nov; 23(11):1553-62. PubMed ID: 25284004
[TBL] [Abstract][Full Text] [Related]
15. An overview of the mTOR pathway as a target in cancer therapy.
Gentzler RD; Altman JK; Platanias LC
Expert Opin Ther Targets; 2012 May; 16(5):481-9. PubMed ID: 22494490
[TBL] [Abstract][Full Text] [Related]
16. The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience.
Bambury RM; Benjamin DJ; Chaim JL; Zabor EC; Sullivan J; Garcia-Grossman IR; Regazzi AM; Ostrovnaya I; Apollo A; Xiao H; Voss MH; Iyer G; Bajorin DF; Rosenberg JE
Oncologist; 2015 May; 20(5):508-15. PubMed ID: 25845990
[TBL] [Abstract][Full Text] [Related]
17. Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma.
Ikeda S; Hansel DE; Kurzrock R
Cancer Treat Rev; 2015 Sep; 41(8):699-706. PubMed ID: 26138514
[TBL] [Abstract][Full Text] [Related]
18. The utility of next generation sequencing in advanced urothelial carcinoma.
Tripathi A; Grivas P
Eur Urol Focus; 2020 Jan; 6(1):41-44. PubMed ID: 31708470
[TBL] [Abstract][Full Text] [Related]
19. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
20. H-RAS mutation is a key molecular feature of pediatric urothelial bladder cancer. A detailed report of three cases.
Castillo-Martin M; Collazo Lorduy A; Gladoun N; Hyun G; Cordon-Cardo C
J Pediatr Urol; 2016 Apr; 12(2):91.e1-7. PubMed ID: 26522772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
